background
rapid
diagnost
test
high
sensit
lower
respiratori
tract
infect
lrti
could
lead
improv
patient
care
reduc
unnecessari
antibiot
use
associ
cost
diagnost
yield
feasibl
cost
realtim
polymeras
chain
reaction
pcr
nasopharyng
oropharyng
swab
specimen
routin
diagnost
workup
lrti
determin
method
random
control
trial
nasopharyng
oropharyng
swab
specimen
patient
admit
antibiot
treatment
lrti
evalu
mean
realtim
pcr
respiratori
virus
atyp
pathogen
well
convent
diagnost
procedur
realtim
pcr
result
patient
intervent
group
report
treat
physician
result
patient
control
group
made
avail
result
total
patient
mean
age
standard
deviat
year
includ
alloc
intervent
group
pathogen
detect
frequent
influenza
viru
patient
streptococcu
pneumonia
coronaviru
staphylococcu
aureu
rhinovirus
realtim
pcr
increas
diagnost
yield
case
patient
case
patient
compar
convent
diagnost
test
detect
viral
pathogen
pcr
associ
winter
season
less
infiltr
chest
radiograph
lower
creactiv
protein
level
shorter
durat
symptom
use
realtim
pcr
result
result
partial
total
cessat
antibiot
treatment
patient
confid
interv
overal
antibiot
use
compar
intervent
group
control
group
median
durat
treatment
vs
day
signific
use
realtim
pcr
increas
treatment
p
p
diagnost
cost
per
patient
conclus
implement
realtim
pcr
etiolog
diagnosi
lrti
increas
diagnost
yield
consider
reduc
antibiot
use
cost
health
econom
burden
communityacquir
lower
respiratori
tract
infect
lrti
due
communityacquir
pneumonia
associ
exacerb
chronic
obstruct
pulmonari
diseas
larg
continu
increas
empir
antimicrobi
therapi
lrti
base
expect
etiolog
role
bacteria
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
legionella
pneumophila
chlamydia
pneumonia
mycoplasma
pneumonia
improv
sensit
laboratori
techniqu
respiratori
virus
recent
identifi
frequent
import
caus
sever
lrti
previous
assum
rapid
identif
viral
etiolog
lrti
may
improv
effect
patient
manag
influenc
decis
whether
withhold
antibiot
treatment
initi
antivir
therapi
implement
infectioncontrol
measur
prevent
transmiss
rapid
assess
viral
bacteri
etiolog
possibl
novel
sensit
highli
specif
taqmanbas
realtim
pcr
assay
appli
biosystem
howev
diagnost
test
costli
diagnost
yield
feasibl
implement
routin
diagnost
workup
evalu
suffici
therefor
random
control
trial
conduct
evalu
feasibl
clinic
econom
impact
use
rapid
taqman
pcr
detect
respiratori
virus
atyp
pathogen
patient
hospit
gener
ward
lrti
set
studi
popul
multicent
random
clinic
trial
conduct
univers
hospit
univers
medic
center
teach
hospit
diakonessenhui
utrecht
netherland
trial
includ
patient
lrti
refer
one
hospit
gener
practition
studi
began
studi
procedur
test
characterist
realtim
pcr
base
previou
research
center
explain
physician
particip
hospit
mean
introductori
present
written
inform
novemb
march
consecut
patient
age
year
admit
one
particip
hospit
need
immedi
antimicrobi
treatment
lrti
elig
inclus
lrti
defin
onset
increas
cough
sputum
product
short
breath
wheez
chest
pain
focal
diffus
sign
chest
examin
well
presenc
least
constitut
symptom
includ
fever
confus
sweat
headach
leukocytosi
pneumonia
defin
lrti
new
progress
infiltr
detect
chest
radiograph
patient
sever
immunosuppress
defin
presenc
neutropenia
neutrophil
count
neutrophilsl
cell
count
cell
mm
concurr
nonrespiratori
infect
requir
antibiot
treatment
sever
lrti
requir
treatment
intens
care
unit
patient
expect
compli
studi
procedur
exclud
studi
approv
medic
ethic
committe
hospit
patient
provid
written
inform
consent
studi
procedur
patient
includ
within
h
admiss
hospit
demograph
data
inform
previou
treatment
durat
symptom
highrisk
comorbid
condit
record
laboratori
test
determin
wbc
count
creactiv
protein
level
chest
radiographi
perform
pathogen
detect
sputum
sampl
avail
blood
sampl
cultur
process
accord
standard
microbiolog
procedur
nasopharyng
sampl
obtain
insert
swab
nostril
parallel
palat
second
absorb
secret
addit
second
swab
posterior
pharynx
tonsillar
area
sampl
urinari
antigen
assay
use
detect
l
pneumophila
binax
within
h
admiss
nasopharyng
oropharyng
swab
specimen
collect
transport
immedi
viral
transport
medium
laboratori
specimen
vortex
centrifug
g
min
supernat
use
viru
isol
realtim
pcr
viru
isol
convent
well
shellvial
cultur
tertiari
monkey
kidney
cell
human
diploid
fibroblast
cell
inocul
ml
clinic
specimen
incub
maximum
day
convent
cultur
examin
twice
weekli
develop
cytopatholog
effect
cultur
posit
result
viru
identifi
immunofluoresc
monoclon
antibodi
adenovirus
influenza
b
virus
respiratori
syncyti
viru
parainfluenza
virus
dako
imagen
rhinovirus
identifi
acidl
test
shellvial
cultur
immunofluoresc
test
use
abovement
monoclon
antibodi
perform
day
cultur
irrespect
develop
cytopatholog
effect
test
detect
viral
atyp
pathogen
perform
parallel
mean
realtim
pcr
specif
influenza
b
virus
respiratori
syncyti
virus
b
coronavirus
parainfluenza
virus
rhinovirus
adenovirus
pneumonia
c
pneumonia
l
pneumophila
realtim
pcr
procedur
perform
describ
elsewher
brief
addit
gener
intern
viru
control
monitor
inhibit
extract
amplif
ml
nasopharyng
swab
oropharyng
swab
supernat
use
total
nucleic
acid
ie
rna
plu
dna
extract
highpur
nucleic
acid
extract
column
roch
diagnost
subsequ
purifi
rna
use
cdna
synthesi
use
random
hexam
appli
biosystem
thereaft
purifi
dna
cdna
use
input
individu
realtim
pcr
reaction
amplifi
use
sequenc
detect
system
appli
biosystem
detect
amplifi
product
perform
use
pathogenspecif
famdyelabel
taqman
probe
pathogen
detect
parallel
amplif
reaction
assay
run
addit
posit
control
neg
control
includ
run
individu
pathogen
assay
result
valid
basi
preset
c
tcriteria
intern
control
posit
control
studi
patient
randomli
alloc
intervent
group
control
group
mean
computergener
tabl
studi
team
avail
h
per
day
enrol
patient
intervent
group
result
realtim
taqman
pcr
report
soon
possibl
h
sampl
obtain
appropri
clinician
mimic
reallif
situat
decis
regard
treatment
chang
result
pcr
analysi
avail
left
discret
physician
control
group
realtim
pcr
perform
result
pcr
analysi
made
avail
treat
physician
physician
compli
hospit
guidelin
describ
hospit
antibiot
formulari
chang
antibiot
treatment
reason
chang
record
followup
outcom
measur
relev
microorgan
cultur
blood
sputum
sampl
detect
urinari
antigen
test
viru
cultur
realtim
pcr
consid
caus
lrti
patient
follow
maximum
day
inhospit
clinic
data
diagnost
procedur
perform
antibiot
use
record
patient
discharg
within
day
admiss
clinic
outcom
health
carerel
cost
discharg
record
outpati
clinic
chang
antibiot
treatment
base
result
pcr
defin
primari
outcom
measur
investig
blind
patient
random
cost
calcul
health
care
perspect
use
calcul
cost
associ
diagnost
intervent
cost
per
patient
calcul
multipli
resourc
use
unit
cost
cost
medic
drug
determin
use
dutch
price
cost
includ
hospit
stay
estim
per
day
includ
standard
diagnost
procedur
cost
realtim
pcr
includ
labor
cost
cost
reagent
depreci
equip
overhead
cost
per
sampl
diagnost
cost
base
price
indic
netherland
colleg
tariff
healthcar
sampl
size
calcul
statist
analysi
control
group
patient
expect
receiv
complet
cours
antibiot
treatment
basi
expect
detect
rate
atyp
viral
pathogen
intervent
group
estim
number
possibl
drop
out
person
would
need
includ
demonstr
reduct
use
antibiot
treatment
statist
analysi
p
b
p
perform
accord
intentiontotreat
principl
differ
valu
continu
variabl
comparison
group
evalu
mean
student
test
normal
distribut
variabl
mean
mannwhitney
u
test
variabl
skew
distribut
x
test
use
test
differ
proport
among
categor
variabl
group
total
patient
mean
age
year
mean
fine
score
includ
studi
random
intervent
group
random
control
group
baselin
characterist
compar
studi
group
slightli
patient
intervent
group
receiv
previou
antibiot
treatment
tabl
etiolog
etiolog
diagnosi
could
made
patient
studi
convent
diagnost
analys
blood
sputum
cultur
urinari
antigen
test
show
potenti
pathogen
lrti
patient
realtim
pcr
increas
diagnost
yield
case
patient
case
patient
patient
standard
cultur
yield
realtim
pcr
detect
pathogen
patient
viru
identifi
pcr
significantli
shorter
durat
symptom
lower
creactiv
protein
level
fewer
chest
radiograph
show
infiltr
admit
frequent
winter
season
compar
pcrneg
patient
tabl
multivari
analysi
best
predict
model
predict
pcr
posit
includ
featur
area
receiv
oper
characterist
curv
ci
intervent
group
result
realtim
pcr
report
mean
durat
h
sampl
patient
posit
result
basi
pcr
result
antibiot
treatment
modifi
patient
intervent
group
patient
treatment
possibl
infect
due
pneumonia
c
pneumonia
l
pneumophila
discontinu
neg
pcr
result
patient
blactam
therapi
continu
definit
etiolog
diagnosi
made
patient
antibiot
treatment
discontinu
pcr
posit
coronaviru
influenza
viru
treatment
adapt
made
control
group
rel
reduct
number
complet
antibiot
cours
ci
treatment
adapt
continu
blactam
treatment
includ
analysi
rel
reduct
ci
patient
treatment
adapt
clinic
cure
day
four
patient
underw
barrier
isol
pcr
indic
infect
influenza
viru
patient
receiv
treatment
neuramidas
inhibitor
clinic
econom
evalu
three
patient
studi
group
die
intervent
group
control
group
durat
antimicrobi
treatment
compar
studi
group
median
durat
day
rang
day
intervent
group
day
rang
day
control
group
signifp
p
icant
mean
antibiot
cost
rang
per
patient
total
antibiot
cost
compar
studi
group
tabl
treatment
neuramidas
inhibitor
ad
per
treat
patient
cost
intervent
group
importantli
use
realtim
pcr
effect
durat
hospit
stay
median
length
stay
day
rang
day
intervent
group
day
rang
day
control
group
reduc
number
extra
diagnost
procedur
requir
exclud
confirm
relat
diagnos
compar
number
addit
cultur
bloodga
analys
ct
angio
scan
bronchoscopi
perform
studi
group
total
cost
per
patient
hospit
diagnost
procedur
treatment
intervent
group
control
group
tabl
intervent
group
actual
antibiot
cost
save
attribut
report
pcr
result
compar
continu
treatment
contrast
save
total
cost
pcr
test
per
patient
thu
patient
includ
analysi
use
realtim
pcr
would
increas
averag
cost
per
patient
treatment
diagnost
cost
per
patient
intervent
group
implement
realtim
pcr
diagnost
workup
patient
hospit
communityacquir
lrti
increas
etiolog
diagnosi
howev
clinic
treatment
patient
hardli
chang
antibiot
partial
total
discontinu
patient
rapid
diagnosi
viral
lrti
reduc
durat
hospit
stay
number
cost
diagnost
procedur
antibiot
despit
advanc
health
care
lrti
still
one
lead
caus
hospit
admiss
mortal
associ
consider
antibiot
use
health
carerel
cost
exampl
communityacquir
pneumonia
respons
hospit
unit
state
year
annual
cost
treat
patient
approxim
billion
addit
consider
overus
antibiot
treatment
lrti
especi
viral
infect
unnecessari
antibiot
use
regard
drive
forc
global
increas
antibiot
resist
clinic
valu
convent
diagnost
method
microbiolog
cultur
gram
stain
guid
treatment
lrti
limit
low
sensit
consider
delay
obtain
result
small
fraction
posit
sampl
gram
stain
sputum
specimen
probabl
lead
great
decreas
antibiot
use
cost
therefor
improv
diagnost
method
polici
decreas
antibiot
use
patient
lrti
necessari
recent
promis
method
evalu
measur
procalcitonin
serum
level
patient
clinic
symptom
lrti
result
signific
decreas
antibiot
use
without
advers
effect
patient
outcom
especi
among
patient
acut
bronchiti
theori
rapid
detect
respiratori
virus
might
also
result
clinic
econom
benefit
beforeaft
studi
rapid
diagnosi
viral
lrti
result
reduct
antibiot
use
children
compar
preced
year
statist
signific
financi
benefit
achiev
adult
patient
anoth
studi
similar
design
drawback
studi
use
immunofluoresc
techniqu
less
sensit
viru
detect
adult
patient
use
histor
control
subject
evalu
cost
outcom
addit
comparison
made
patient
viral
infect
identifi
present
studi
use
sensit
realtim
pcr
patient
admit
lrti
increas
econom
benefit
compar
contemporari
control
group
costeffect
realtim
pcr
could
improv
increas
diagnost
yield
decreas
cost
assay
increas
diagnost
yield
could
achiev
ad
pathogen
test
panel
recent
discov
human
metapneumoviru
coronavirus
perform
realtim
pcr
sputum
sampl
rather
nasopharyng
oropharyng
swab
specimen
howev
patient
studi
cohort
produc
adequ
sputum
sampl
durat
symptom
time
pcr
invers
relat
likelihood
posit
test
result
perform
realtim
pcr
earlier
cours
lrti
might
also
increas
diagnost
yield
netherland
patient
first
seen
gener
practition
patient
sever
clinic
present
respond
empir
treatment
refer
hospit
whether
realtim
pcr
costbenefici
outpati
clinic
generalpractic
popul
region
patient
initi
seen
gener
practition
remain
determin
altern
cost
might
decreas
reduc
number
select
pathogen
test
panel
establish
select
criteria
patient
examin
exampl
patient
admit
winter
season
recent
onset
symptom
low
creactiv
protein
level
absenc
infiltr
chest
radiograph
like
viral
pathogen
detect
limit
realtim
pcr
test
highrisk
patient
may
increas
costeffect
final
physician
hesit
discontinu
antibiot
treatment
even
pcr
detect
viru
possibl
bacteri
cultur
result
avail
pcr
result
avail
therefor
doubt
rapid
report
result
may
possibl
near
futur
expens
autom
system
lead
improv
costeffect
realtim
pcr
might
costeffect
clinician
would
less
reluct
chang
clinic
manag
basi
test
result
studi
protocolbas
morerigor
patient
manag
need
address
issu
conclus
although
rapid
detect
respiratori
virus
mean
realtim
pcr
increas
number
detect
pathogen
consider
test
result
hardli
influenc
clinic
manag
patient
reduc
addit
diagnost
procedur
antibiot
use
antibiot
cost
durat
hospit
stay
